Codexis Inc (CDXS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $127.13M
Last updated: Nov 17, 2026 at 11:04 AM ET
Codexis Inc (CDXS) Competitors
The companies most similar to Codexis are Coherus BioSciences (CHRS), Anixa Biosciences (ANIX) and Cellectis SA (CLLS). By market cap, Codexis ranks 8th of the 13 companies on this page; Palisade Bio (PALI) is the largest at $201.01M.
Peer Comparison
CDXS's revenue growth of 124.0% is above the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Codexis (CDXS) | $127.13M | N/A | N/A | -21.8% | N/A | 124.0% | 0.00% |
| Coherus BioSciences Inc (CHRS) | $81.21M | N/A | 1.5x | -253.4% | -144.8% | 23.4% | 0.00% |
| Anixa Biosciences Inc (ANIX) | $91.08M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Cellectis SA (CLLS) | $118.86M | N/A | 1.8x | 0.0% | -74.1% | -85.4% | 0.00% |
| Cassava Sciences Inc (SAVA) | $114.97M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Korro Bio, Inc. (KRRO) | $186.81M | N/A | 175.8x | 0.0% | -82.8% | -43.1% | 0.00% |
| Sutro Biopharma (STRO) | $163.03M | N/A | 3.4x | 0.0% | N/A | -6.1% | 0.00% |
| Atrium Therapeutics, Inc. Common Stock (RNA) | $162.00M | N/A | 3.3x | -180.9% | -44.5% | 24.2% | 0.00% |
| Pyxis Oncology Inc (PYXS) | $188.98M | N/A | 11.6x | 0.0% | N/A | 0.0% | 0.00% |
| Compass Therapeutics Inc. (CMPX) | $139.35M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Palisade Bio Inc (PALI) | $201.01M | N/A | 436.8x | 0.0% | N/A | 0.0% | 0.00% |
| Corbus Pharmaceuticals Holding (CRBP) | $69.86M | N/A | 13.9x | 0.0% | -106.7% | -100.0% | 0.00% |
| PolyPid (PYPD) | $132.25M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $135.80M | N/A | 7.5x | 0.0% | -82.8% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Codexis, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Coherus BioSciences Inc (CHRS) | Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. | CHRS competitors |
| Anixa Biosciences Inc (ANIX) | Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. | ANIX competitors |
| Cellectis SA (CLLS) | Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors... | CLLS competitors |
| Cassava Sciences Inc (SAVA) | Cassava Sciences, Inc., a clinical-stage biotechnology company, develops drugs for neurodegenerative diseases. The company is headquartered in Austin, Texas. | |
| Korro Bio, Inc. (KRRO) | Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare... | KRRO competitors |
| Sutro Biopharma (STRO) | Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. | STRO competitors |
| Atrium Therapeutics, Inc. Common Stock (RNA) | Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. | RNA competitors |
| Pyxis Oncology Inc (PYXS) | Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb)... | PYXS competitors |
| Compass Therapeutics Inc. (CMPX) | Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple... | CMPX competitors |
| Palisade Bio Inc (PALI) | Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. | PALI competitors |
| Corbus Pharmaceuticals Holding (CRBP) | Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target... | CRBP competitors |
| PolyPid (PYPD) | PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX)... | PYPD competitors |
Frequently Asked Questions About CDXS
Who are Codexis' main competitors?
The companies most similar to Codexis include Coherus BioSciences (CHRS), Anixa Biosciences (ANIX), Cellectis SA (CLLS), Cassava Sciences (SAVA) and Korro Bio (KRRO), listed from the closest match.
Who is Codexis' biggest competitor?
Palisade Bio (PALI) is the largest of the similar companies at $201.01M; Coherus BioSciences (CHRS) is the closest match by business profile, size, sector and industry.
How does CDXS stock compare with its competitors?
CDXS' net margin is -21.8% against a peer median of 0.0%.
Which of Codexis' competitors pays a higher dividend?
Codexis pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Codexis bigger than its competitors?
No. Codexis is 8th by market cap among the 13 companies on this page; the largest is Palisade Bio (PALI) at $201.01M.
CDXS pages: Overview, Earnings, Forecast, Financials, Competitors